Literature DB >> 12457717

Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes.

S H Kok1, C Y Hong, M Y P Kuo, C H K Lee, J J Lee, I U Lou, M S Lee, M Hsiao, S K Lin.   

Abstract

Norcantharidin (NCTD) is the demethylated analogue of cantharidin. In this study, multi-parameter assessments of morphological alterations, clonogenic efficiency, cell growth curves, DNA synthesis, and DNA strand break were employed to determine and compare the cytotoxic effects of NCTD on oral cancer KB cell line and normal buccal keratinocytes. The results showed NCTD induced significant cytotoxicity in KB cells after 24 h of exposure. Normal buccal keratinocytes were more resistant to NCTD induced cytotoxicity. The IC(50) of 24 h NCTD treatment for KB and keratinocytes were 15.06 and 216.29 microg/ml, respectively with a keratinocyte/KB selective index of 14.36. Anoikis and membrane blebbing, morphological characterization of apoptosis, were observed in about 90% of KB cells after exposure to 100 microg/ml of NCTD for 24 h compared to about 30% in keratinocytes. In addition, inhibition of colony formation was noted in KB cells even when exposed to low concentration of drug (5 microg/ml) for a short period of time (6 h). NCTD inhibited subsequent cell proliferation in KB but growth of normal keratinocytes was retarded only temporarily. NCTD inhibited DNA synthesis in both KB and normal keratinocytes. However, keratinocytes were more sensitive to DNA synthesis inhibition by low dose of NCTD. Significant DNA strand break was noted in KB cells only after cell viability was reduced to less than 60% of the control. In comparison, normal keratinocytes were resistant to NCTD induced DNA strand break. These results indicated KB cells were more sensitive to NCTD induced cytotoxicity compared to normal keratinocytes. NCTD may be of value in treating oral cancers. The underlying mechanisms of the differential actions of NCTD on these two cell types are worthy of further investigations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12457717     DOI: 10.1016/s1368-8375(01)00129-4

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  20 in total

Review 1.  Norcantharidin, a protective therapeutic agent in renal tubulointerstitial fibrosis.

Authors:  Ying Li; Yan Ge; Fu You Liu; You Ming Peng; Lin Sun; Jun Li; Qiong Chen; Yan Sun; Kun Ye
Journal:  Mol Cell Biochem       Date:  2011-09-29       Impact factor: 3.396

2.  Norcantharidin induces autophagy-related prostate cancer cell death through Beclin-1 upregulation by miR-129-5p suppression.

Authors:  Wenjun Xiao; Bo Dai; Yao Zhu; Dingwei Ye
Journal:  Tumour Biol       Date:  2015-12-05

3.  Norcantharidin impairs medulloblastoma growth by inhibition of Wnt/β-catenin signaling.

Authors:  Flora Cimmino; Maria Nunzia Scoppettuolo; Marianeve Carotenuto; Pasqualino De Antonellis; Valeria Di Dato; Gennaro De Vita; Massimo Zollo
Journal:  J Neurooncol       Date:  2011-07-07       Impact factor: 4.130

4.  Effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells.

Authors:  Yue-Zu Fan; Jin-Ye Fu; Ze-Ming Zhao; Cun-Qiu Chen
Journal:  World J Gastroenterol       Date:  2005-04-28       Impact factor: 5.742

5.  Norcantharidin induces melanoma cell apoptosis through activation of TR3 dependent pathway.

Authors:  Shujing Liu; Hong Yu; Suresh M Kumar; James S Martin; Zhanyong Bing; Weiqi Sheng; Marcus Bosenberg; Xiaowei Xu
Journal:  Cancer Biol Ther       Date:  2011-12-01       Impact factor: 4.742

Review 6.  Targeting the unfolded protein response in head and neck and oral cavity cancers.

Authors:  Daniel W Cole; Peter F Svider; Kerolos G Shenouda; Paul B Lee; Nicholas G Yoo; Thomas M McLeod; Sean A Mutchnick; George H Yoo; Randal J Kaufman; Michael U Callaghan; Andrew M Fribley
Journal:  Exp Cell Res       Date:  2019-05-07       Impact factor: 3.905

7.  Cantharidins induce ER stress and a terminal unfolded protein response in OSCC.

Authors:  Y Xi; D M Garshott; A L Brownell; G H Yoo; H-S Lin; T L Freeburg; N G Yoo; R J Kaufman; M U Callaghan; A M Fribley
Journal:  J Dent Res       Date:  2014-11-25       Impact factor: 6.116

8.  Norcantharidin inhibits renal interstitial fibrosis by downregulating PP2Ac expression.

Authors:  Tao Hou; Zheng Xiao; Ying Li; Yan-Hua You; Hua Li; Yu-Ping Liu; Yi-Yun Xi; Jun Li; Shao-Bin Duan; Hong Liu; Lin Sun; You-Ming Peng; Fu-You Liu
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

9.  Norcantharidin modulates miR-655-regulated SENP6 protein translation to suppresses invasion of glioblastoma cells.

Authors:  Zhenxing Zhang; Xiaofeng Song; Xu Feng; Ye Miao; Honglei Wang; Yang Li; He Tian
Journal:  Tumour Biol       Date:  2015-11-25

10.  Novel norcantharidin-loaded liver targeting chitosan nanoparticles to enhance intestinal absorption.

Authors:  Yong-yan Bei; Xiao-yan Chen; Yang Liu; Jing-yu Xu; Wen-juan Wang; Zong-lin Gu; Kong-lang Xing; Ai-jun Zhu; Wei-liang Chen; Lin-seng Shi; Qin Wang; Xue-nong Zhang; Qiang Zhang
Journal:  Int J Nanomedicine       Date:  2012-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.